On February 10, Andon Health Co.Ltd(002432) announced the record of investor relations activities, which shows that from the perspective of supply and demand, the supply of Amazon platform kit products may be related to the changes of the epidemic situation. The number of new cases in Omicron in the United States increased from the end of December last year to the middle of January this year, and now the number of new cases per day is lower than before, There may be a mismatch between supply and demand.
In response to the decline of new cases in overseas Omicron, Andon Health Co.Ltd(002432) said that public information shows that the number of new cases in the United States has decreased compared with the previous period. If the U.S. government starts distributing kits free of charge, it may have some impact on the company’s online and offline sales.
Some investors suggested that some European countries have lifted restrictions on covid-19 recently, which may affect the demand for detection in the future. In this regard, Andon Health Co.Ltd(002432) said that in the future, assuming that covid-19 virus becomes an ordinary flu or is treated as an ordinary flu, covid-19 detection may become a routine business to provide users with testing needs, and the corresponding detection demand should also decline.
For the proportion of government orders and commercial orders in the future, Andon Health Co.Ltd(002432) said that epidemic factors should still be considered. If the epidemic is serious in the later stage, the growth of government orders may exceed that of commercial orders; If the epidemic is normalized in the later stage, the proportion of retail sales may increase relatively.
According to the announcement, Andon Health Co.Ltd(002432) takes a conservative attitude towards the issue of production capacity. It believes that the issue of production capacity needs to consider China’s supply chain capacity, including raw material supply capacity, production sites, labor resources, epidemic development, changes in demand and other factors.
For the production capacity in February and future production capacity planning, Andon Health Co.Ltd(002432) said that the company now has some experience to deal with the production capacity adjustment of epidemic changes. If it is considering expanding other markets, the company may give priority to some countries with high access threshold.
Andon Health Co.Ltd(002432) said in the announcement that the company has considered the layout of comprehensive antibody testing, but this depends on the guidance requirements of the FDA for the approval of comprehensive antibodies. On the other hand, it depends on the changes of covid-19 epidemic situation, that is, if covid-19 becomes the type of daily influenza, there may be demand for products that can detect multiple viruses.
In addition, some investors asked questions about the competitive barriers of certification in the U.S. market. In this regard, Andon Health Co.Ltd(002432) said that the challenge of obtaining FDA EUA authorization for its covid-19 test kit products is mainly the need to do clinical and performance tests in the United States, the time and speed of clinical, and the compliance with clinical requirements. The local team in the United States played a role in the process of applying for authorization.
